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FL, USA) and those who received EES (Xience V TM , Abott Vascular, Santa Clara, CA, USA). We enrolled patients with a maximum of 2 de novo coronary artery lesions with length <30 mm and vessel diameter ≥2.5-≤4.0 mm. Tolerance of dual antiplatelet therapy had been checked for all enrolled patients and continued for at least 1 year after PCI. The primary endpoint was the rate of restenosis at 8-month follow-up, defined as angiographic luminal diameter >50% by quantitative coronary angiography (QCA). The secondary endpoints included clinical follow-up data of major adverse cardiac events after the PCI procedure, including all-cause death, nonfatal myocardial infarction, and target lesion revascularization (TLR). Intracoronary 2.5-5 mg doses of isosorbide dinitrate were administered before the initial, final, and follow-up angiograms to achieve maximal vasodilatation. Contrast-filled guide catheters were used as the reference standard in QCA. Matched end-diastolic frames of the angiograms before and after PCI and at 8-month follow-up were analyzed using a contour detection minimum cost algorithm (QCA-CMS Version 3.0, MEDIS, Leiden, The Netherlands). Restenosis was defined as a stent stenosis >50% in diameter anywhere within the stent and/or within the 5-mm borders proximal or distal to the stent. Late lumen loss was defined as the difference between minimal lumen diameter (MLD) immediately after PCI and on 8-month follow-up angiography. Types of coronary lesions were characterized according to the American Heart Association/American College of Cardiology (AHA/ACC) classification. 20 QCA analyses were performed by an experienced technician who was blinded to the assignment to groups.
The study protocol was approved by the hospital's ethics committee, and the physicians obtained written informed consent from each patient.
Statistical Analysis
Continuous variables are presented as mean ± standard deviation values. Univariate analysis of differences between the SES and EES groups was performed with the 2-tailed unpaired t-test for continuous outcome variables and by chi-square or Fisher exact tests for discrete outcome variables. Logistic regression analysis models were used to assess univariate and multivariable covariates associated with progression to the 8-month follow-up restenosis. All the prognostic variables with P<0.05 
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were entered into a logistic multivariable model in order to determine independent predictors. Differences were considered significant at P<0.05. All statistical analyses were performed using SPSS (SPSS, Chicago, IL, USA).
Results

Baseline Characteristics
A total of 50 patients with 73 lesions were assigned to SES and 50 patients with 74 lesions to EES. All patients underwent successful PCI with the assigned stent implantation without in-hospital complications, including death or the necessity for additional surgical procedure. Table 1 shows the baseline characteristics in the SES and EES groups. No significant difference was detected in the lesion characteristics or QCA data ( Table 2) . Figure.
Cumulative distribution curves of diameter stenosis immediately after percutaneous coronary intervention (PCI) procedure and at follow-up angiography. Diameter stenosis after PCI procedure was similar between the 2 stent groups. Percent diameter stenosis at 8-month follow-up was significantly higher in the SES group than in the EES group (P=0.0024). EES, everolimus-eluting stent; SES, sirolimus-eluting stent. SAKAKIBARA T et al.
Even after adjusting for other risk factors at baseline, EES remained an independent predictor of preventing restenosis after PCI (OR 0.20; 95% CI 0.05-0.78; P=0.022) ( Table 4) . MLD at baseline was also an independent predictor of restenosis in the follow-up period. Clinical follow-up data during the year after PCI was obtained for all patients. The incidence of the composite endpoint including all-cause death, nonfatal myocardial infarction and TLR was 22.0% in the SES group and 10.0% in the EES group (P=0.10). There was no significant difference between the SES and EES groups in the rates of all-cause death and nonfatal myocardial infarction (2.0% vs. 2.0%, P>0.99, and 4.0% vs. 4.0%, P>0.99, respectively). Implantation of EES was of borderline significance in TLR, because of stent restenosisinduced ischemia (18.0% vs. 6.0%, P=0.064). There was no event related to in-stent thrombosis in either group. The stenttreated vessel was not a culprit lesion in any patient who experienced acute myocardial infarction after stent implantation.
Discussion
We found that the use of EES was as safe as that of SES, but in addition, the EES significantly prevented restenosis in patients on maintenance HD compared with the SES. Recent studies have found that implantation of EES reduces the risk of restenosis and major adverse cardiovascular events, 15-19 but until now, data on the EES concerning clinical outcomes after PCI in HD patients have been lacking. We have provided additional information on the safety and efficacy of the EES in HD patients who are at high risk of cardiac events.
PCI has been widely performed in HD patients with coronary artery disease, 4,5 but these patients frequently have complex lesions, resulting in higher restenosis rates after PCI. 21 Moreover, the atherosclerotic process and inflammation may affect progressive intimal hyperplasia after SES implantation. 22-24 Thus, a higher restenosis rate remains a major clinical limitation in HD patients even in the era of first-generation DES. 7-14 From these points of view, our findings might be of great significance.
In the meta-analysis by Stone et al, EES performed less well in patients with diabetes. 25 In the present study, however, there was no difference in the restenosis rate in the EES patients with and without diabetes (data not shown). However, some mechanisms can possibly explain why the EES reduced restenosis compared with the SES. Complex morphologies such as calcified lesions are frequently seen in HD patients, compared with non-HD patients, 21,26 and in that regard the implantation of EES in calcified lesions is associated with favorable reduction of restenosis and repeat revascularization 19 compared with previously reported stent studies. The drug itself, its release and the polymer of each DES also possibly affects the results. Severe inflammation, which is probably related to the polymer rather than the drug, is frequently seen with the Cypher TM stent compared with the Xience V TM stent. 27 Furthermore, the Xience V TM stent, which was used as the EES in the present study, has a thinner strut (0.0032 inches) compared with that of the Cypher TM stent (0.0055 inches). It has been reported that the use of coronary stents with thinner struts significantly reduces restenosis after stent implantation. 28 These mechanisms may be related to less arterial injury and less hypersensitivity reactions, resulting in prevention of restenosis. In addition, a study has suggested that more rapid endothelialization is seen after implantation of the EES compared with the SES and paclitaxel-eluting stent. 18 Overall, the EES has beneficial effects as shown in our results.
In the present study, the rate of incidence of major adverse events was similar between the 2 groups. It has been reported that restenosis is associated with increased risk of death after PCI, 29 so it is possible that preventing restenosis may improve clinical outcome. Furthermore, there are some reports of late complications, such as very-late stent thrombosis and latecatch up phenomenon, after SES implantation, although there are limited data on the EES in this context. Thus, we should collect more long-term data.
Study Limitations
First, the present trial was a single-center design. Because there were limited data from which we might obtain the magnitude of the effects, we did not perform a sample size calculation to justify the number of subjects enrolled. However, we enrolled 100 HD patients in 5 months. In the situation, approximately 500 PCIs were performed each year. In addition, half of such patients undergo HD because the center has a large dialysis center. Thus, the number of enrolled patients during 5 months was not so high for this institution. Second, all patients were Japanese. A study has reported that Japanese have a better prognosis than subjects in other countries. 30 Third, the rate of use of rotational atherectomy might be low, because we used intravascular ultrasound in PCI and rotational atherectomy was used for severe calcified lesions across which intravascular ultrasound could not cross. Fourth, we did not collect angiographic 8-month follow-up for all patients, although we Tables 1,2 .
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did evaluate clinical follow-up data for all patients.
Conclusions
The present study demonstrated that HD patients have a markedly lower restenosis rate with clinical safety after implantation of the EES, compared with the SES. Implantation of the EES during PCI might be a good strategy for HD patients with ischemic heart disease.
